Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of Zorblisa in epidermolysis bullosa
NL-OMON43935Phase 3Active, not recruiting
- Sponsor
- Scioderm
- Start
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of allantoin in epidermolysis bullosa (EB), sponsored by Scioderm. Primary endpoint: Long-term safety of Zorblisa. Started Oct 2015; status: active, not recruiting.
02
Drugs
allantoin
03
Conditions
epidermolysis bullosa (EB)
Beyond the preview
Go deeper on NL-OMON43935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43935.